抗抑郁药停药症状的发生率与性质:系统综述与荟萃分析
标准化量表显示停药1周时症状数平均仅比安慰剂或继续用药组多1个症状,未达临床显著停药综合征阈值。头晕、恶心、眩晕和紧张不安的 odds 增加,但抑郁症状未因停药而加重,提示停药后出现的抑郁为复发。
要点
- 停药1周时DESS评分平均仅多1个症状,低于临床显著停药综合征阈值。
- 停药后头晕、恶心、眩晕、紧张不安的 odds 较安慰剂停药增加,头晕最常见。
- 停药未伴随抑郁症状加重,停药后出现的抑郁提示复发而非停药症状。
核心结论
- 停用抗抑郁药后第1周平均停药症状数低于临床显著停药综合征阈值。
- 停药与抑郁症状无关联,停药后出现的抑郁提示抑郁复发。
研究设计与样本
- 系统综述与荟萃分析,检索 Embase、PsycINFO、Ovid MEDLINE 和 Cochrane Library 至2023年11月7日。
- 采用随机效应模型计算标准化均数差,并行比例和 odds ratio 荟萃分析,另进行亚组分析比较不同抗抑郁药。
主要发现
- 停药1周时DESS评分较安慰剂或继续用药组升高,标准化均数差0.31(95% CI 0.23-0.39),相当于多1个症状(k=11,n=3915)。
- 停药后头晕(OR 5.52,95% CI 3.81-8.01)、恶心(OR 3.16,95% CI 2.01-4.96)、眩晕(OR 6.40,95% CI 1.20-34.19)和紧张不安(OR 3.15,95% CI 1.29-7.64)的 odds 较安慰剂停药增加。
- 头晕是最常见的停药症状,风险差6.24%。
- 停药与抑郁症状无关联(基于5项研究)。
关键数值与推荐
- DESS标准化均数差0.31(95% CI 0.23-0.39;k=11;n=3915),相当于多1个症状。
- 头晕 OR 5.52(95% CI 3.81-8.01),恶心 OR 3.16(95% CI 2.01-4.96),眩晕 OR 6.40(95% CI 1.20-34.19),紧张不安 OR 3.15(95% CI 1.29-7.64)。
- 头晕风险差6.24%。
临床怎么用
- 临床可告知患者停药后可能出现头晕、恶心、眩晕和紧张不安,但症状数平均较轻。
- 停药后若出现抑郁症状,应评估为抑郁复发而非停药症状。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The incidence and nature of discontinuation symptoms following antidepressant cessation remain unclear. OBJECTIVE: To examine the presence of discontinuation symptoms using standardized scales (eg, Discontinuation-Emergent Signs and Symptoms [DESS]) and the incidence of individual discontinuation symptoms in individuals who stop taking antidepressants. DATA SOURCES: The databases Embase, PsycINFO, Ovid MEDLINE, and Cochrane Library were systematically searched from inception until November 7, 2023. STUDY SELECTION: Randomized clinical trials (RCTs) reporting discontinuation symptoms using a standardized scale or individual symptoms (eg, adverse events) following antidepressant cessation were included. DATA EXTRACTION AND SYNTHESIS: Data extracted were cross-checked by 2 reviewers. Additional unpublished data from 11 RCTs were included. A random-effects meta-analysis was conducted to calculate standardized mean difference between individuals who discontinued an antidepressant vs those who continued an antidepressant or discontinued placebo. A proportion and odds ratio (OR) meta-analysis was performed to assess incidence of individual discontinuation symptoms compared to placebo. Subgroup analyses were conducted to compare different antidepressants. Data analysis was conducted between September 2024 and December 2024. MAIN OUTCOMES AND MEASURES: The primary outcomes were incidence and nature of antidepressant discontinuation symptoms measured using standardized or unstandardized scales. RESULTS: A total of 50 studies were included, 49 of which were included in meta-analyses. The 50 studies included 17 828 participants in total, with 66.9% female participants and mean participant age of 44 years. Follow-up was between 1 day and 52 weeks. The DESS meta-analysis indicated increased discontinuation symptoms at 1 week in participants stopping antidepressants (standardized mean difference, 0.31; 95% CI, 0.23-0.39; number of studies [k] = 11; n = 3915 participants) compared to those taking placebo or continuing antidepressants. The effect size was equivalent to 1 more symptom on the DESS. Discontinuation of antidepressants was associated with increased odds of dizziness (OR, 5.52; 95% CI, 3.81-8.01), nausea (OR, 3.16; 95% CI, 2.01-4.96), vertigo (OR, 6.40; 95% CI, 1.20-34.19), and nervousness (OR, 3.15; 95% CI, 1.29-7.64) compared to placebo discontinuation. Dizziness was the most prevalent discontinuation symptom (risk difference, 6.24%). Discontinuation was not associated with depression symptoms, despite being measured in people with major depressive disorder (k = 5). CONCLUSIONS AND RELEVANCE: This systematic review and meta-analysis indicated that the mean number of discontinuation symptoms at week 1 after stopping antidepressants was below the threshold for clinically significant discontinuation syndrome. Mood worsening was not associated with discontinuation; therefore, later presentation of depression after discontinuation is indicative of depression relapse.
引用
- Kalfas M, Tsapekos D, Butler M, et al. Incidence and Nature of Antidepressant Discontinuation Symptoms: A Systematic Review and Meta-Analysis. JAMA Psychiatry. 2025. PMID: 40632531. doi:10.1001/jamapsychiatry.2025.1362
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。